Clinical Research Behind Our Formulas

Researchers compared three daily NMN amounts with placebo in healthy middle-aged adults. The study assessed blood NAD concentrations, physical performance measures, biological age estimates, and safety outcomes.

The 500 mg Pacific Formulations serving falls between the 300 mg and 600 mg study groups. This makes the trial relevant to the serving range, though it was not a direct test of a 500 mg dose or of the finished Pacific Formulations product.

This trial examined daily NMN intake, blood NAD metabolites, motor function tests, sleep measures, and stress-related questionnaires. The NMN group received 250 mg per day, which equals one Pacific Formulations capsule and half of the labeled serving.

Adults with self-reported poor sleep quality were assigned to magnesium bisglycinate or placebo. Researchers measured insomnia severity and related psychological questionnaires across the study period.

The study used the same mineral form as the Pacific Formulations powder and a daily elemental amount 50 mg above our serving. Results should not be treated as proof that a 200 mg serving will produce the same findings.

This trial tested 250 mg of daily magnesium in healthy middle-aged women and measured body composition and muscle strength. It offers context for a nearby elemental amount, but magnesium oxide differs from magnesium glycinate in form and absorption characteristics.

Published research has examined combined myo-inositol and D-chiro-inositol in a 40:1 ratio, with outcomes tied to menstrual regularity, ovarian function, hormone measures, and markers of insulin response in selected groups.

The ingredient ratio matches the Pacific Formulations formula. The total daily amount used in many studies is higher than our single four-capsule serving, so the results should not be presented as a direct test of our labeled daily intake.

This systematic review assessed controlled trials of inositol for PCOS and helped inform the 2023 international evidence-based guideline update. The authors reported that dose, ratio, study quality, and outcomes varied across trials.

This source offers a broader view of the evidence and its limits. It should not be read as proof for one serving size or as a replacement for care from a qualified clinician.

Researchers studied berberine hydrochloride taken before meals and measured glucose, insulin, triglycerides, HDL cholesterol, waist measures, and other metabolic markers.

The trial used 300 mg more berberine per day than the Pacific Formulations serving. Its findings should not be treated as proof that 1,200 mg will produce the same outcome.

This trial reported that 1 g of daily berberine did not reduce the primary measures of visceral fat area or liver fat in the full study group. The study also assessed safety and several secondary metabolic markers.

Including neutral or negative findings gives a more complete view of the evidence. A clinical research page should show where an ingredient did not meet the trial's main goal, not only where a favorable result was reported.

Researchers measured anthropometric, liver, and metabolic outcomes after 12 weeks of berberine or placebo. This study used a nearby daily dose but focused on a clinical population, so its results should not be generalized to every healthy adult.

Resistance-trained men and women received placebo or 5 g of creatine monohydrate within one hour before or after training. Researchers assessed resistance-training adaptations and body composition.

The ingredient form and daily amount match the Pacific Formulations serving. The finished product itself was not tested, and the results apply to the study's trained population and exercise plan.

Published sports-medicine research describes a short loading phase followed by a lower daily maintenance amount. A loading phase raises muscle creatine stores faster, but regular maintenance dosing can also raise stores over a longer period.

Pacific Formulations provides 5 g per scoop, which sits at the upper end of the common daily maintenance range. The serving also makes a four-times-daily loading schedule easy to measure when used under the suggested protocol.

This multicenter trial studied 10 g of collagen hydrolysate per day in adults with primary knee osteoarthritis. Researchers assessed joint-related symptoms over six months.

The daily amount is close to the 11 g Pacific Formulations serving. The trial involved a diagnosed population and should not be used to claim that collagen treats arthritis or joint disease.

Two controlled trials measured skin hydration, dermal collagen density, and collagen fragmentation after daily oral collagen peptide intake. Reported findings included changes in measured skin hydration after eight weeks.

Peptide composition can differ between collagen ingredients, so research on a named or proprietary collagen peptide should not be treated as a direct test of every hydrolyzed collagen powder.

This review gathered randomized, double-blind controlled trials that measured skin wrinkles, hydration, elasticity, and firmness after oral hydrolyzed collagen intake. It offers a broader view of the evidence but includes different collagen ingredients and serving amounts.